Biomarkers

BACKGROUND: Clinicians' views on clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBM) are not well understood. METHOD: The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Biofluid-Based Biomarkers Professional Interest Area conducted a survey to elicit clinician opinions on AD BBM implementation, including contexts of use, assay selection, reporting and result interpretation. RESULT: Clinician respondents (n = 212) practiced in Europe (56%), North America (24%), Caribbean and Central or South America (11%) and other continents (9%). Most respondents were medical doctors (80%) practicing in secondary or tertiary care (88%) (Table 1). For 56% of respondents, CSF AD biomarkers or amyloid PET were accessible, but 48% agreed and 52% disagreed with implementation of AD BBM in any clinical context (Table 2). Respondents emphasized the need for data from diverse populations and educational resources to support test interpretation. CONCLUSION: Surveyed clinicians generally agreed with published appropriate use recommendations but were divided on AD BBM readiness for clinical use.